Application of the Latest Data in CLL/SLL: Guidance for Current and Future Treatment Strategies

Application of the Latest Data in CLL/SLL: Guidance for Current and Future Treatment Strategies

Friday, December 9, 2022
Webinar -- 7:30 AM CT


  • NCCN guidelines review for first-line and second-line regimens
  • Key variables in deciding between regimens
  • Mastering the current regimen components
    • Including MOA, key efficacy and safety data, and other considerations with BTK inhibitors, BCL-2 inhibitors, PI3K inhibitors, and anti-CD20 mAbs
  • Case discussions: putting it all together for effective management of CLL
  • On the horizon: MRD, CAR T-cell therapy, and other hot research areas
  • Audience Question and Answer Session


Brian Hill, MD

Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Deborah Stephens, DO

Associate Professor
Department of Hematology
Huntsman Cancer Center Institute
University of Utah
Salt Lake City, Utah

Jennifer Woyach, MD

Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, Ohio

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in the optimal management of patients with CLL/SLL.

Target Audience
This educational program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan therapeutic approaches for treatment-naive and relapsed/refractory CLL/SLL, taking into consideration the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference
  • Appraise the differences in selectivity, binding, efficacy, and adverse event profiles of agents with the similar molecular target used to treat CLL/SLL
  • Develop treatment plans to address unique clinical challenges, based on the available evidence and recommendations outlined in the NCCN Guidelines to optimize outcomes for patients with CLL/SLL
  • Evaluate the evolving role of measurable residual disease (MRD; often referred to as minimal residual disease), allogeneic hematopoietic cell transplant, and CAR T-cell therapy


Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

NCCN designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
NCCN designates this educational activity for a maximum of 2.0 contact hours.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 2.0 contact hours (0.2 CEUs) of continuing education credit. Universal Activity Number: JA4008196-0000-22-097-L01-P

Attention Pharmacists:
You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once the post-test and evaluation are completed. Before completing these requirements, be sure your NCCN profile has been updated with your NABP e-profile ID and date of birth or your credit cannot be reported. If you have not already done so, please complete your e-profile at to obtain your NABP e-Profile ID.

Physician Assistant Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content will be reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, will be fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Disclosure of Unlabeled Use 
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.